IceCure Medical Secures Patent Approval for Advanced Cryoprobes
IceCure Medical Limited (NASDAQ: ICCM) is thrilled to announce that it has obtained a Notice of Allowance from the United States Patent and Trademark Office. This new patent, titled "Cryoprobe," is a remarkable advancement in their cutting-edge cryoablation technology.
The innovative design focuses on significantly enhancing the process of cryoprobe extraction, which ultimately minimizes the risk of tissue trauma during treatment. By improving this extraction method, IceCure aims to reduce costs while elevating the overall patient experience.
XSense™ System and Regulatory Approvals
The XSense™ System and its accompanying cryoprobes have recently gained regulatory approval in the U.S. This approval marks a significant milestone in expanding the accessibility of their minimally-invasive cryoablation treatments. These intricate systems are designed to destroy tumors through freezing, offering a promising alternative to standard surgical procedures.
Eyal Shamir, IceCure's Chief Executive Officer, expressed enthusiasm regarding the advancements in their technology. He stated, "The cryoablation platform is at the forefront of our industry, and the introduction of this new cryoprobe technology is revolutionary. It integrates safety features such as temperature monitoring and controlled gas pulses, ultimately leading to improved patient outcomes. This allows clinicians to manage the extraction process with enhanced precision."
Innovative Features of the Cryoprobe Technology
The new cryoprobe technology is particularly notable due to its unique design. The probe's tip includes advanced features such as a built-in heater, temperature sensors, and precise gas control. This functionality allows healthcare professionals to measure and adjust the temperature of the cryoprobe surface—even when it is embedded in frozen tissue. This level of control is essential for ensuring patient safety and preserving healthy tissue.
With compatibility across different cryoprobe types in the XSense™ system, IceCure's new technology provides a versatile solution for diverse clinical applications. This adaptability is indicative of their commitment to addressing various patient needs and improving cryoablation's efficiency.
Understanding IceCure's Cryoablation Systems
IceCure's platform technology encompasses both the ProSense® and XSense™ Cryoablation Systems. These state-of-the-art systems utilize liquid nitrogen to generate lethal zones for efficient tumor destruction, effectively targeting benign and cancerous lesions in different bodily locations, including the breast, kidney, lung, and liver.
Apart from focusing on tumor eradication, IceCure's cryoablation systems significantly enhance patient comfort. They accelerate recovery time, reduce pain, and diminish the risks associated with traditional surgical interventions. The transportable design of both systems facilitates a more convenient experience for physicians and patients alike.
About IceCure Medical Limited
IceCure Medical (NASDAQ: ICCM) stands at the forefront of developing and marketing innovative cryoablation therapies. Their focus is primarily on treating tumors by employing liquid nitrogen and freezing methods. The company's technology offers a less invasive alternative to surgical tumor removal, emphasizing safety and effectiveness during short treatment procedures.
IceCure has successfully launched its flagship ProSense® system globally, with authorizations across several regions, including the U.S., Europe, and Asia. This outreach has significantly broadened patient access to their advanced cryotherapy solutions.
Frequently Asked Questions
What is the significance of IceCure's new patent?
The new patent enhances cryoprobe extraction, reducing tissue trauma and costs, improving patient experiences.
What regulatory approvals has IceCure received recently?
IceCure's XSense™ System and its cryoprobes received regulatory clearance in the U.S. and other regions.
How does the new cryoprobe technology work?
The cryoprobe includes a heater and sensors to manage its temperature, ensuring safe extraction during cryoablation.
What types of tumors do IceCure's systems target?
IceCure technologies treat benign and cancerous tumors in various organs, including breast, kidney, lung, and liver.
How does IceCure enhance patient comfort during procedures?
IceCure's systems are designed to minimize pain, accelerate recovery and streamline the treatment process for patients.
